Johnson & Johnson has done something quietly remarkable this week: it has rallied far enough that the stock now trades above every single price at which its executives have sold over the past three weeks.
The insider theme that dominated the last two notes has not resolved — it has simply been outrun by the tape. CEO Joaquin Duato disposed of roughly $44.7 million worth of stock between August 5 and August 13, with the bulk executed between $261 and $262. EVP Jennifer Taubert sold 15,000 shares at $263.36 on August 17. The 90-day net selling figure across all executives had crossed $61 million with no purchases on record. The closing price reported for the Buenos Aires listing sits at ARS 28,700, which reflects the local peso-denominated trading of the same underlying shares — the US-listed price is the relevant anchor, and on that basis the stock has gained roughly 4.7% on the week and more than 9% over the past month. Each of those insider sale prices is now in the rear-view mirror.
The positioning data offers little friction to the rally. JNJ's short-score rank sits at the 77th percentile and utilization ranks in the 76th percentile — both elevated — but these are structural features of a mega-cap pharmaceutical name rather than a signal of imminent squeeze pressure. The dividend factor score ranks in the 90th percentile, reflecting the stock's long-standing yield appeal to income-oriented holders. EPS momentum over 30 days is softer, ranking in the 27th percentile, though forward earnings growth ranks at the 78th percentile — suggesting the near-term estimate trend is flat even as the longer-term picture looks constructive.
The institutional base is broadly stable and incrementally adding. BlackRock holds 8.8% of shares and added just over a million shares in the most recent reporting period. Vanguard and State Street added smaller increments. Capital Research and Management added 2.3 million shares through June, and T. Rowe Price increased its position by 6.5 million shares — one of the larger institutional additions in the holder table. None of these moves are aggressive, but together they describe a passive-to-active base that is not reducing exposure into the same rally that executives are selling into.
Earnings are next on October 13. The two most recent prints produced a one-day decline of just over 1% each time, followed by a five-day recovery to a modest gain. The prior quarter's print saw a sharper one-day drop of 4.7%, with a five-day loss of 2.6%. The pattern is not one of sustained post-earnings weakness — more a brief sell-the-news response before buyers return. With the stock up more than 30% year-to-date and trading above recent insider sale prices, the October print will test whether the pharmaceutical segment's forward earnings growth (the 78th-percentile ranking) is translating into numbers the Street can point to, or whether the litigation overhang — talc and ovarian cancer cases — surfaces as a line-item reminder.
The story heading into the next seven weeks is whether the gap between where insiders exited and where the stock currently trades continues to widen, or whether October earnings give sellers the catalyst that planned-disposal programmes alone have not provided.
See the live data behind this article on ORTEX.
Open JNJ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
